Search

Pomalidomide prolongs survival in refractory myeloma patients

MM-003 is a large, multi-centre phase 3 study that assessed the efficacy and safety of a new drug, Pomalidomide (POM) in combination with low-dose dexamethasone (POM+LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage…

Read more

Call for interest — new La Cantera event

The call for interest is closed at 23:59 on November 30, 2024. In 2025, EHA will provide funding for a new La Cantera coaching event.

Read more

European Hematology Curriculum

Harmonization of hematology knowledge is part of EHA’s mission. The first step in harmonizing hematology training is to stipulate the required fields of knowledge, each with its recommended level of competence.

Read more

Granulocytes & Constitutional Marrow Failures Disorders

The Specialized Working Group (SWG) on Granulocytes and Constitutional Marrow Failure Syndromes (G&CMFS) derives from the fusion of the formerly existing SWG on Granulocyte and Monocyte Disorders with other initiatives, grown within the EHA environment, related to Constitutional Marrow Failure…

Read more

EHA Innovation Grant draft

The call will open on October 15, 2024, at 12:00 (CEST).

Read more